Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV 3373

Drug Profile

ABBV 3373

Alternative Names: ABBV-3373; Anti-TNF GRM ADC; anti-TNF-GRM-antibody-drug-conjugate-Abbvie; Human anti-TNF GRM ADC

Latest Information Update: 14 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Anti-TNF monoclonal antibodies; Antirheumatics; Drug conjugates; Immunoconjugates; Steroids
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 10 Oct 2022 No development reported - Phase-II for Rheumatoid arthritis in Poland (IV), Puerto Rico (IV), Israel (IV), Netherlands (IV), Hungary (IV) (Abbvie pipeline October 2022)
  • 10 Oct 2022 No development reported - Phase-II for Rheumatoid arthritis in USA (IV) (Abbvie pipeline)
  • 02 Jun 2021 Pharmacokinetics data from a phase I part of phase IIa trial in Rheumatoid Arthritis presented at the 22nd Annual Congress of the European League Against Rheumatism (EULAR-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top